Liver cancer symptoms appear late requiring high-risk screening

Liver cancer (hepatocellular carcinoma) presents minimal early-stage warning signs, with symptoms like abdominal pain or weight loss indicating advanced progression.

In Plain English: The Clinical Takeaway

• Silent Progression: Early-stage liver cancer rarely causes symptoms, meaning physical discomfort usually points to an advanced stage.
• High-Risk Surveillance: Individuals diagnosed with chronic hepatitis B, chronic hepatitis C, or liver cirrhosis must undergo screening every six months.
• Multi-Modality Care: Treatment options range from surgical resection and radiofrequency ablation to transarterial chemoembolization (TACE), depending on tumor size and underlying liver function.

Epidemiological Burden and Survival Trajectories

As reported by SisaJournal and Fnnews, hepatocellular carcinoma (HCC) constitutes approximately 75% of primary malignant liver tumors, with 담도암 (cholangiocarcinoma) making up the remainder. Data compiled in 2023 place liver cancer as the seventh most common malignancy overall in South Korea, accounting for 5.1% of all cancer diagnoses. The demographic distribution skews notably by sex; the disease ranks fifth in male cancer incidence, while dropping to eighth among female populations.

Photo: Vietnam.vn

Global comparisons underline the heavy regional burden across Asia. International Agency for Research on Cancer (IARC) GLOBOCAN estimates project nearly 600,000 new cases in Asia, contrasted with roughly 5,000 in Oceania. In Vietnam, liver and intrahepatic bile duct cancers represent the fourth most frequently diagnosed malignancy, with men facing twice the risk of women. Globally, the World Health Organization (WHO) estimates roughly 240 million chronic carriers of hepatitis B, with approximately 1.1 million annual deaths driven largely by subsequent cirrhosis and hepatocellular carcinoma.

Primary Etiologies and the Phenomenon of Referred Pain

Chronic infection with hepatitis B (HBV) and hepatitis C (HCV) viruses remains the predominant driver of malignant transformation in the liver. Prolonged viral activity causes chronic hepatic inflammation, culminating in the fibrotic tissue scarring characteristic of cirrhosis. Additional risk factors include heavy alcohol consumption, tobacco use, and obesity.

While classical symptoms remain absent during early stages, tumor expansion can occasionally trigger atypical presentations. Enlargement of the hepatic capsule can irritate adjacent neural pathways, causing the central nervous system to misinterpret the signal as referred pain in the right shoulder.

Diagnostic Protocols and High-Risk Screening Mandates

To bypass the diagnostic hurdles of late-stage presentation, clinical guidelines emphasize structured surveillance for vulnerable populations. Individuals managing chronic hepatitis B, chronic hepatitis C, or established liver cirrhosis are designated as high-risk groups.

Photo: 파이낸셜뉴스

In South Korea, individuals aged 40 and older who fall into these high-risk categories qualify for state-sponsored screening programs, which fund both diagnostic modalities biannually. When an ultrasonographic nodule is identified, clinicians utilize computed tomography (CT) or magnetic resonance imaging (MRI) for definitive characterization. Lesions measuring under one centimeter frequently necessitate multi-phasic imaging comparison, close interval follow-up, or targeted needle biopsy to confirm malignancy.

Treatment Stratification and Therapeutic Modalities

Therapeutic decision-making depends heavily on preserved functional reserve within the hepatic parenchyma alongside tumor dimensions and multifocality. When hepatic reserve is robust and malignant lesions are localized, curative strategies involve surgical resection or local ablation techniques such as radiofrequency ablation, which utilizes thermal energy to destroy neoplastic tissue.

Photo: 헬스조선

When disease dissemination spans multiple segments or advances beyond localized boundaries, palliative interventions are deployed. These include transarterial chemoembolization (TACE), which infuses cytotoxic chemotherapy directly into the tumor-feeding hepatic artery before embolizing the vessel, alongside systemic pharmacological regimens.

Preventative Measures and Lifestyle Realities

Primary prevention centers on widespread immunization against the hepatitis B virus and adherence to strict sterile protocols during medical, dental, or body-modification procedures to block iatrogenic transmission. For individuals already managing chronic viral hepatitis, sustained antiviral therapy suppresses viral replication and significantly reduces long-term oncogenic risk. Direct-acting antivirals currently achieve cure rates exceeding 95% for hepatitis C infections, transforming the management landscape.

Conversely, popular health misconceptions regarding dietary supplements and moderate alcohol consumption face correction in recent clinical literature. Fnnews and SisaJournal report that contemporary studies dismantle the long-standing belief that occasional wine consumption yields health benefits, establishing that even low-level alcohol intake lacks proven safety margins. Furthermore, commercially available liver health supplements lack rigorous clinical validation for cancer prevention.

Contraindications & When to Consult a Doctor

Individuals undergoing TACE or localized ablation require continuous post-treatment surveillance every two to six months due to elevated recurrence rates.

References

• World Health Organization (WHO) & International Agency for Research on Cancer (IARC): Global Cancer Statistics and Viral Hepatitis Burden.
• Korean Association for the Study of the Liver (KASL): Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma.
• National Health Insurance Service (NHIS) South Korea: National Cancer Screening Program Guidelines.